About ARGX

Argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Argenx is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Argenx ability to execute on this focus is enabled by its suite of differentiated technologies. Argenx SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows it to exploit novel and complex targets, and its three antibody engineering technologies are designed to enable it to expand the therapeutic index of its product candidates.
Primary Exchange: NASDAQ

ARGX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 263.9 M 2.63946E+08 234 234 0.16% 0.00158307 862 K 862004
UBIO Proshares UltraPro Nasdaq Biotechnology 33.0 M 3.30408E+07 228 228 0.09% 0.000897237 94 K 94441
ADRD Invesco BLDRS Developed Markets 100 ADR Index Fund 37.1 M 3.71E+07 83 83 0.11% 0.00113 41 K 41268
ADRU Invesco BLDRS Europe Select ADR Index Fund 12.9 M 1.29E+07 69 69 0.13% 0.00134 17 K 17063
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.0 B 2E+09 1,004 1004 0.01% 0.000121398 237 K 237145
IBB iShares Nasdaq Biotechnology Index Fund 8.3 B 8.31808E+09 222 222 0.35% 0.0035 29.1 M 2.91458E+07

Wait, Before You Leave...